TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Sera Prognostics (NASDAQ:SERA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Institutional and Insider Ownership
82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 6.2% of TScan Therapeutics shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and price targets for TScan Therapeutics and Sera Prognostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TScan Therapeutics | 1 | 5 | 2 | 0 | 2.12 |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
TScan Therapeutics presently has a consensus target price of $2.67, suggesting a potential upside of 1,305.73%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 169.61%. Given TScan Therapeutics’ higher possible upside, equities research analysts clearly believe TScan Therapeutics is more favorable than Sera Prognostics.
Profitability
This table compares TScan Therapeutics and Sera Prognostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TScan Therapeutics | -1,655.35% | -108.72% | -54.47% |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
Risk and Volatility
TScan Therapeutics has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Earnings & Valuation
This table compares TScan Therapeutics and Sera Prognostics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TScan Therapeutics | $10.32 million | 1.25 | -$129.77 million | ($0.91) | -0.21 |
| Sera Prognostics | $80,000.00 | 1,005.98 | -$31.93 million | ($0.67) | -3.04 |
Sera Prognostics has lower revenue, but higher earnings than TScan Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Sera Prognostics beats TScan Therapeutics on 8 of the 15 factors compared between the two stocks.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
